Diligence memo · auto-generated · as of July 2, 2026

Micromet, Inc.

Micromet, Inc. has raised $175M over 1 round; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Micromet, Inc. operates in Biotechnology, based in Rockville.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Micromet, Inc. has raised $175M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $175M on 2012-03-07.

Most recent recorded round closed around 2012-03-07.

Valuation (modeled)modeled

Provath models Micromet, Inc. at approximately $7.2B (range $795M–$15.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Last raise 14.3 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).

Modeled value ranks above 100% of those peers.

Closest niche peers: BioMotiv, LLC, Sangart Inc, Arena Pharmaceuticals Inc.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.